Andrew Guggenhime Sells 42,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 42,000 shares of the stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,429,294.37. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Wednesday, September 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $115.94, for a total value of $927,520.00.

Vaxcyte Stock Up 0.2 %

Shares of Vaxcyte stock opened at $112.32 on Friday. The company has a market cap of $12.54 billion, a PE ratio of -24.00 and a beta of 0.99. The business has a 50 day moving average price of $104.73 and a 200-day moving average price of $83.63. Vaxcyte, Inc. has a 52 week low of $45.61 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the prior year, the business posted ($0.70) EPS. As a group, research analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Institutional Investors Weigh In On Vaxcyte

Institutional investors and hedge funds have recently modified their holdings of the company. Darwin Global Management Ltd. grew its holdings in shares of Vaxcyte by 374.3% during the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after purchasing an additional 2,170,845 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the period. Capital Research Global Investors raised its stake in shares of Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after acquiring an additional 700,414 shares during the last quarter. Janus Henderson Group PLC raised its position in Vaxcyte by 9.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after purchasing an additional 692,492 shares during the last quarter. Finally, Avoro Capital Advisors LLC purchased a new stake in Vaxcyte in the first quarter worth $39,278,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PCVX has been the subject of a number of recent research reports. BTIG Research boosted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group raised their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Leerink Partners lifted their target price on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC increased their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.